



Earnings Presentation

FY 2025

February 2026



Disclaimer



This presentation has been prepared by PureHealth (the “Company”) for general use only and is not necessarily comprehensive as it has not been independently verified, nor is it considered or constitutes part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or solicitation to buy or subscribe for any securities, and does not constitute an offer, invitation or recommendation in connection with the purchase, ownership or sale of any securities of PureHealth.

The Company does not offer any representation or warranty, express or implied, regarding the accuracy, completeness, or correctness of the information or opinions contained in this presentation, and no person or legal entity should rely for any purpose on the information contained in this presentation. This presentation may include statements that are or may be considered “forward-looking statements” regarding the Company’s financial position, results of operations and business, and certain of PureHealth’s plans, expectations, assumptions, and objectives, which are for general update only and do not constitute an invitation or inducement to engage in any investment activity.

The information contained in this presentation, including but not limited to forward-looking statements, is current as of the date of this presentation and is not intended to provide any assurances about future outcomes. Figures and percentages in this document may not precisely total due to rounding.

By attending this presentation or receiving this document, you acknowledge and agree that you will not rely on the information contained herein without conducting your own due diligence and consulting with your own financial, legal, tax, or other professional advisors. The Company and its affiliates, officers, directors, employees, and agents expressly disclaim any liability for any direct or indirect loss or damage arising from the use of or reliance on this presentation or its contents. To the fullest extent permitted by applicable laws, this presentation and its contents are proprietary to PureHealth. It may not be reproduced, redistributed, or disseminated, in whole or in part, without the prior written consent of the Company.




Contents

Performance and Operational Highlights	4
Overview & Strategy	9
Our Operating Model Driving Synergies	11
Strategic Execution & Value Creation	14
Circle's Turnaround: Deep Dive	19
Segment Review	25
Financial Review	33
Outlook & Guidance	40
Appendix	42



A Transformation Leader Across Healthcare and Insurance

Expanding our Footprint, Deepening our Market Leadership



World-Class Operations and Facilities, Fuelled by Focused Strategy and Platform Synergies

Care (Healthcare)

Hospitals Diagnostics Procurement Technology

Cover (Insurance)

Health Insurance Property & Casualty

Notes: PureHealth's investment in US publicly listed Ardent Health (ARDT) is classified as a minority equity investment (21%)



FY 2025 Performance Highlights

Strong full-year performance, reflecting broad-based momentum across both Care and Cover verticals.
PureHealth’s Board recommends a dividend of AED 600.6 million, equivalent to 30% of distributable Net Profit.

Group Financial Results (YoY)		Care (Healthcare)				Cover (Insurance)	
		Hospitals	Diagnostics	Procurement	Technology	Health Insurance	
Revenue	AED 27.3 Bn +6% ▲	Patient Interactions				Gross Written Premium	AED 7.6 Bn +9% ▲
EBITDA	AED 4.8 Bn +16% ▲	11.0 Mn +16% ▲					
Net Profit	AED 2.0 Bn +18% ▲	Revenue				Revenue	AED 7.8 Bn +13% ▲
EPS	AED 0.18 +17% ▲	AED 19.6 Bn +3% ▲					
FCF Conversion	80% +1.0ppts ▲	EBITDA				Net Profit	AED 802 Mn +53% ▲
Return on Equity (ROE)	10.6% +1.0ppts ▲	AED 3.8 Bn +10% ▲					

Notes: Patient Interactions includes UAE hospitals and clinics along with International. Care vertical also includes Eliminations. HHG consolidated from 1st October 2025. Net Profit refers to net profit attributable to owners. Dividends are subject to AGM approval and will be paid on a semi-annual basis.

FY 2025 Key Operational Highlights

Driving strategic growth through transformation, operational efficiencies, tech-enablement and targeted acquisitions.

Care (Healthcare)




Expansion of Advanced Specialized and Complex Care Services

SEHA launched a **Liver Transplant program**, adding high-acuity capability with **33 liver transplants** in 2025

Expanded **Transplant Nephrology**, performed **130 Kidney transplants** in 2025 and **794** to date

Delivered the world's first ITVISMATM Gene-Replacement Therapy for the treatment of **Spinal Muscular Atrophy**

Established Adult Cardiothoracic surgery offering **Al Ain region's** only dedicated service



Development of Specialized Centers & Advanced Care Capabilities

Expanded **complex care capabilities**, including an **advanced EP lab for cardiac care**, and multiple first-in-Abu Dhabi interventions (e.g; Auditory Brainstem Implant, and Hypoglossal Nerve Implant for sleep apnea)

Opened the Paediatric Epilepsy Monitoring Unit to accommodate the growing need for specialised epilepsy monitoring in children

Launched **Globus Excelsius GPS robotic system** to advance complex spine surgery through improved precision, safety & efficiency



Expanded Patient Care

Expanded patient access through extended operating hours, new specialty services and **optimized patient scheduling** and **referral pathways**

Expanded outpatient capacity by adding new specialized clinics within existing facilities and **opened six additional clinics** across new geographic areas (Saadiyat, Masoudi, Rowda, etc.)

Increased **physician workforce** by over **350** to support continued growth in care delivery



Capacity Expansion

Enhanced IP bed capacity with 170 bed additions and further increased occupancy of **SEHA from 74% to 76%**

Increased OR **capacity and operational hours**, including weekend and extended after-hours elective services

Introduced **Advanced PET Scanning Services** in SEHA, with **771 studies performed** within last six months

FY 2025 Key Operational Highlights

Driving strategic growth through transformation, operational efficiencies, tech-enablement and targeted acquisitions.

Care (Healthcare)



Strategic Partnerships

SEHA entered a landmark strategic partnership with Cincinnati Children's to deliver world-class paediatric expertise in the MENA region

SEHA partnered with **Schoen Clinic Group**, Germany's leading rehabilitation & mental healthcare provider, to deliver world-class In-patient & Out-patient rehabilitation services in UAE

Circle Health Capacity Expansion

Strengthened Circle Health's clinical footprint through targeted bolt-on acquisitions, including **Fairfield Independent Hospital** (28 beds and two operating theatres) and the **Meriden Hospital Advanced Imaging Centre**

Further expanded capacity with new outpatient centres in Cheshire and Inverness, alongside the expansion of cardiology services

Acquisition of HHG

Successfully completed the **€800 million¹** acquisition of a 60% stake in Hellenic Healthcare Group, the number one private healthcare group operating **11 hospitals and 23 diagnostic centres** across Greece and Cyprus

Cover (Insurance)



Daman Acquires P&C Insurance License

Strategic expansion through recently acquired license into the high-growth **Property and Casualty (P&C) insurance segment**

Marking transformation from a mono-liner to a multi-liner Insurance provider

¹ EUR 800 million represents 60% of equity value

FY 2025 Key Operational Highlights

Driving strategic growth through transformation, operational efficiencies, tech-enablement and targeted acquisitions.

Care (Healthcare)



MENA's Largest AI-powered Diagnostic Lab

Launched MENA's largest and most **advanced AI-powered standalone diagnostic laboratory** under **PureLab**

The facility is designed to process more than **30 million sample tests annually** across a comprehensive range of pathology, molecular, and specialised diagnostics



Rafed's Landmark Partnerships

Rafed was appointed as the Abu Dhabi Department of Health's Exclusive Distributor for **Unified Purchasing Program (UPP)**, a government led procurement initiative

Rafed partnered with Abu Dhabi government to create a **Regional Vaccine Distribution Hub**, delivering world-class vaccine distribution across the Middle East, Africa, and South Asia



Advancing AI, Automation and Operational Excellence

Group-wide optimization & digital transformation through launch of **AI Factory**, enabling scalable and compliant AI deployment across Group

Rolled out a unified Health Information System across PureHealth facilities

Inhouse Cyber Security services expanded to our assets across **UK and Greece**

Over **100 technology initiatives delivered in 2025**

Cover (Insurance)



Digital Transformation

Daman advanced its digital transformation agenda with the launch of its **first AI-based document intelligence solution**

The platform now processes over **60 million documents annually**, significantly reducing manual effort while improving accuracy and turnaround times



Overview & Strategy



Strategy Focused on Growth, a Patient-Centered Ecosystem and Technological Enablement



Solidify Growth In Core Platforms

- **Market share expansion across key platforms** by leveraging scale and strategic positioning
- **Stronger earnings visibility and margin expansion** driven by capabilities enhancement and operational scale-up
- Margin and revenue growth bolstered by scaling **high-complexity procedures**



Unlocking Growth Through Digital and AI Enablement

- **Monetizing patient ecosystem through advanced digital capabilities**, driving efficiency, data-driven insights and value creation across the network
- **AI-powered solutions, analytics and predictive models** elevate operational and clinical efficiencies across the network



Strategic Expansions through M&A

- **Strategic global expansion focused on value creation**, and aligned with core healthcare competencies
- **Seamless integration of acquired assets** to accelerate synergies and operational consistency

48 Million+ Patient Touchpoints (+17% YoY)



SAKINA's care, now on Pura

You can now book your session with SAKINA's licensed psychologists and psychiatrists online. Anytime, anywhere.

**Our Operating
Model Driving
Synergies**

UAE's Largest Integrated Healthcare Network: PureHealth's Value Proposition and Unique Model



Insurance & Financing

1 DIGITAL FRONT DOOR


- Centralized Digital Access and Customer Stickiness
- Always-On Service Model
- Tele-consultation, E-Pharmacy, Diagnostics etc.

2 PRIMARY CARE NETWORK

- First Contact Point with Wide Network of Clinics
- Referral Ecosystem Directing Patients to our Network Hospitals
- Offering Integrated Clinical Pathways


3 TERTIARY CARE NETWORK

- Delivering High-Acuity and Complex Care
- Regional Hub for Complex Care
- Centre of Excellence & Advanced Technologies



Platform Synergies Through a Horizontal and Vertical Ecosystem

PureHealth is an Integrated Operating Platform with strategy, performance management and value creation driven centrally and executed consistently across the network.





Strategic Execution & Value Creation



UAE Care – Executing for Scale, Complexity, and Returns

2025 KPIs (YoY)

+15%	+14%	+8%	+10%
OP Volumes	IP volumes	Revenue ¹	EBITDA



Strategic Focus



2025 Delivered

Expand Patient Reach and Access

- **Network Optimization:** Delivered strong volume growth and utilization recovery across SEHA through strategic portfolio management
- **Capacity Expansion:** Increased patient access via STMC activation, facility expansions, and extended operating hours

Service Complexity & Clinical Partnerships

- **Tertiary Excellence:** Scaled advanced care with 163 organ transplants and expanded specialized cardiac, paediatric, orthopedic, and oncology services
- **Global Partners:** Executed strategic partnerships with Cincinnati Children’s and Schoen Clinic

Technology-Enabled Operational Excellence

- **Digital Transformation:** Deployed AI-enabled diagnostics and automation to streamline clinical and administrative workflows
- **Operational Governance:** Embedded group-wide discipline and accountability to strengthen execution across the organization

¹ Adjusted for UPP & internal revenue eliminations



UAE Cover – Scaling a Resilient, High-Performance Insurance Platform

2025 KPIs (YoY)

+9%
GWP

+7%
Claims Processed

+6%
Members Insured

+13%
Revenue

+53%
Net Profit



Strategic Focus



2025 Delivered

Strengthen the Core Insurance Platform

- **Profitable Scaling:** Delivered YoY growth in GWP and membership while maintaining lean operational excellence
- **Proven Retention:** Sustained portfolio health through rigorous underwriting standards and consistent service quality

Diversify Earnings & Reduce Risk Concentration

- **Multi-Line Pivot:** Secured the P&C license, fundamentally de-risking the business through non-medical diversification
- **Market Readiness:** Completed all pre-launch requirements for Property, Business, Energy, and Aviation verticals

Enable Growth Through Technology & Partnerships

- **Infrastructure Ownership:** Migrated to a proprietary core system, lowering IT overhead and labor dependency
- **Intelligent Automation:** Integrated AI for claims and fraud; scaled reach via Amanak (SME) and AXA Global Health partnerships



International – Scaling Platforms and Unlocking Value Through Integration

2025 KPIs (YoY)



+21%

Total Patient Interactions

+20%

Revenue

+19%

EBITDA



Strategic Focus



2025 Delivered

**Build Scaled International Platforms
(Buy & Build)**

- **Platform Expansion:** Finalized HHG acquisition and bolt-on growth across the UK, Greece, and Cyprus
- **Capacity Optimization:** Scaled Circle facilities with high-demand outpatient and imaging additions at Fairfield and Meriden

Strengthen Governance & Operating Model

- **Unified Governance:** Established International Business Cluster with standardized Group-wide KPIs and frameworks
- **Operational Synergy:** Streamlined procurement and reporting systems to ensure consistent cross-border performance

Drive Value Through Integration & Synergies

- **Portfolio Pivot:** Shifted focus toward high-margin, high-acuity specialties including Orthopaedics, Oncology, and Robotics
- **Digital Integration:** Deployed Group platforms (PureNet, PureCS) across Circle and HHG to centralize cybersecurity and diagnostics and commercially launched Pura in the UK



Disciplined M&A Creating a Global Integrated Platform

Executing a Clear Buy-and-Build Strategy for Value Accretive M&A and Bolt-ons

Strategic rationale for international expansion...

Growth

- Scalable, growth and margin-accretive markets
- Favourable demographics and rising healthcare needs
- Underpenetrated healthcare systems

Stability

- Stable macroeconomic and political environments

Resilience



- Revenue diversification
- Currency diversification through revenues in AED (USD-pegged), GBP, and EUR, providing a natural hedge
- Balanced exposure across high-growth and mature markets

...to create value by accelerating profitable growth

- Synergies across care delivery, diagnostics, and digital health
- Market diversification to strengthen platform resilience
- Operational leverage and margin expansion through scale



Both international assets acquired have high EBITDA Margins and mature currencies compared to many emerging markets


FY 2025	 Circle Health Group	 HHG Hellenic Healthcare Group
EBITDA Margin %	20.9%	20.5%



Circle Health Turnaround: Deep Dive



Circle Turnaround: Executing a Strategic Shift from General Elective Care to High-Acuity, Profitable Specialist Services



Moving From a General Elective Provider to a High-acuity, Technology-led Specialist Platform



Service and Capacity Expansion

Inorganic (Buy and Build via Bolt-on Acquisitions)

- Acquired **Fairfield Independent Hospital** (28 beds, 2 theatres) and **Meriden Hospital Advanced Imaging Centre**

Organic growth initiatives

Footprint and asset rationalisation to optimise utilisation and productivity:

- Expanded primary care footprint to **30+ sites**
- Opened Cheshire Clinic and Inverness Outpatient Centre
- Launched Glasgow Physio Centre, a flagship physiotherapy facility
- Enhanced MRI capability and expanded Occupational Health and Cardiology, supporting upstream patient capture



Moving From a General Elective Provider to a High-acuity, Technology-led Specialist Platform



High-Acuity Growth Through Clinical Excellence

- **Strategic pivot to higher-acuity, higher-margin** specialties including orthopaedics, cardiology, oncology, robotics and complex general medicine
- **Sustained growth in high-complexity procedures**, reflecting strengthened clinical capability and specialist depth
- Increased exposure to **sticky demand** and defensible patient pathways

Robotic assisted clinical excellence

- **Built Europe's largest Velys robotics fleet** (18 systems)
- Scaled advanced platforms including **Da Vinci, MAKO and ROSA**, alongside spinal robotics and next-generation technologies across the network




Moving From a General Elective Provider to a High-acuity, Technology-led Specialist Platform



Margin Expansion Through Integration and Productivity

- **Portfolio-wide operational optimisation**, driven by standardisation and procurement efficiencies
- **Case-mix shift, workforce optimisation and capital structure improvements**, delivering procurement gains, vendor dispute resolution and digital conversion uplift
- **Improved operational and financial performance**, driven by volume growth and efficiency gains, despite a mature market, NHS activity reductions and higher taxes





Circle and PureHealth Group Synergies

Integrating Group capabilities to drive cost efficiency, clinical depth, and platform scale



Governance & Strategy

- Reconstituted the Board and management
- Standardised governance, policies, KPIs, and financial reporting
- Implemented strategy roadmap



Technology & Digital

- PureNet as the digital healthcare platform across Circle
- PureCS-led cybersecurity, online diagnostics booking, and digital infrastructure
- Pura as a digital healthcare product in the UK



People & Organisation

- Physician exchange programmes between Circle and SEHA
- International secondments and placements to support talent development



Procurement

- Group Procurement improving prices and reducing pharmaceutical and consumable costs



Clinical Excellence

- Orthopaedic services by Circle in Al Ain
- Oncology services by SEHA across the Circle network



Diagnostics & Imaging

- PureLab pathology including reference lab services
- Radiology outsourcing of Circle via SEHA tele-radiology, improving access and efficiency






Segment Review



Care: Strong Growth Across Key Metrics

Healthcare






Notes: Care vertical includes Hospitals, Diagnostic, Procurement, Technology and Eliminations. Outpatient and Inpatient volumes includes UAE hospitals and clinics along with UK hospitals. HHG volumes are included within OP & IP from Q4'25



UAE Care: c.1 Million Outpatients Volume Growth Covering both Citizens and Expats


Healthcare



Notes: Care vertical includes Hospitals, Diagnostic, Procurement, Technology and Eliminations. Outpatient and Inpatient volumes includes UAE hospitals and clinics.



Continued Investment in Bed Capacity across Abu Dhabi Emirate






Note: 2023 includes, Bed count and Occupancy for SSMC and NRC for like for like comparison | SSMC was consolidated within PureHealth w.e.f. 1st February 2024



UAE Care: Strong Growth Across Key Metrics

Healthcare





Notes: Care vertical includes Hospitals, Diagnostic, Procurement, Technology and Eliminations



UAE Care: Patient-Driven Growth Supported by Service Expansion

Healthcare



Commentary



- UAE Care delivered normalized revenue¹ of AED 14.0bn in FY 2025, up 8% year-on-year, with Q4 2025 revenue of AED 3.7bn, representing 5% YoY growth
- **Revenue growth was driven by higher patient volumes**, supported by capacity expansion, new clinic openings, extended operating hours, and physician additions
- **EBITDA increased by 10% YoY in FY2025**, reflecting strong operating leverage as expansion initiatives came online
- Normalised EBITDA margins expanded to 16.4%, supported by scale benefits and the integrated healthcare model

¹ Adjusted for UPP & internal revenue eliminations. On reported basis UAE Care generated AED 12.4bn of revenue in FY 2025 and 2.8bn in Q4'25 with EBITDA margin of 18.7% and 22.1%, respectively




International Care: Robust Growth in Core Specialties

Healthcare



Commentary

- **Circle delivered 8% topline growth in FY 2025**, driven by accelerated performance across inpatient, day-case and outpatient services, supported by a higher-acuity case mix and increased revenue per patient
- Circle's **EBITDA margins remained in line with FY 2024**, despite absorbing a negative impact of c. **AED 44m** from National Insurance Contribution changes, supported by favourable case mix, increased clinical complexity and pricing optimisation
- Hellenic Healthcare Group demonstrated **strong early momentum**, with **Q4 FY25 patient volumes up 7% YoY**, driven primarily by outpatient growth in line with HHG's strategic priorities




¹ Includes Outpatient, Inpatient and Day Cases. HHG is consolidated from 01/10/2025



Cover: Strong Results Across All Metrics

Insurance





Financial Review



Group: Robust Revenue Growth Trajectory with Higher Margins

AED Mn	Q4 2024	Q4 2025	Δ%	FY 2024	FY 2025	Δ%
Revenue	6,892	7,211	+4.6%	25,848	27,312	+5.7%
EBITDA	993	1,311	+32.1%	4,119	4,781	+16.1%
Margin	14.4%	18.2%	+3.8pp.	15.9%	17.5%	+1.6pp.
Profit before tax	250	498	+99.4%	1,778	2,242	+26.1%
Margin	3.6%	6.9%	+3.3pp.	6.9%	8.2%	+1.3pp.
Net Profit	279	470	+68.1%	1,716	2,020	+17.7%
Margin	4.1%	6.5%	+2.4pp.	6.6%	7.4%	+0.8pp.

Commentary

- **Group revenue maintained strong momentum through Q4**, underpinning a solid FY 2025 performance. Hellenic Healthcare Group contributed AED 742 million to Group revenue in Q4
- **Group EBITDA rose 16.1% YoY to AED 4.8 billion** in the full year, with **margins expanding to 17.5%**. Despite regulatory headwinds in both the UAE and the UK, performance remained robust across the Care and Cover segments
- Performance in Q4 was further supported by the **contribution from HHG**, which added AED 152 million to EBITDA at a **strong margin of 20.5%**
- **Net profit increased 17.7% YoY to AED 2.0 billion**. While the effective corporate tax rate rose from 9% to 15% in FY25 under the Pillar Two framework, the Group delivered an **improved net profit margin of 7.4%**, highlighting resilient profitability and disciplined operational execution



Care: Revenue & EBITDA Growth Supported by Capacity Expansion

Healthcare

AED Mn	Q4 2024	Q4 2025	Δ%	FY 2024	FY 2025	Δ%
Revenue	5,108	5,173	+1.3%	19,011	19,554	+2.9%
EBITDA	896	1,116	+24.6%	3,474	3,808	+9.6%
Margin	17.5%	21.6%	+4.1pp.	18.3%	19.5%	+1.2pp.
Profit before tax	169	319	+88.6%	1,198	1,330	+11.0%
Margin	3.3%	6.2%	+2.9pp.	6.3%	6.8%	+0.5pp.
Net Profit	204	309	+51.5%	1,190	1,218	+2.3%
Margin	4.0%	6.0%	+2.0pp.	6.3%	6.2%	-0.1pp.

Commentary

- **Care revenue grew by over 3% YoY in FY 2025**, driven by **higher patient** and **diagnostics volumes**, supported through ongoing capacity and service expansion, and the Q4 contribution from the integration of HHG
- **FY 2025 saw improvements in both EBITDA and EBITDA margin**, underpinned by continued efficiency gains and service enhancements, which helped offset regulatory pressures in both the UAE and the UK. The addition of **HHG in Q4** provided an **incremental uplift to EBITDA growth**
- Net profit in FY 2025 was impacted by non-operational items¹ and a higher effective tax rate of 15%, compared with 9% last year, following the implementation of Pillar Two tax requirements
- Normalizing for these factors and excluding HHG, **net profit margin expanded by 130 basis points to 7.7%**, up from to 6.4% in the prior year

Note: Care includes Hospitals, Diagnostic, Procurement and Technology and Eliminations and Adjustments.

¹ Share of profit in Ardent was reclassified from being an associate to an investment at fair value post its listing in July 2024. Also, the current period includes the PPA intangibles, Yas Clinic Group / ADSCC was divested at the beginning of Q2'24



Cover: Sustained Revenue Growth with Strong Margins Improvement

Insurance

AED Mn	Q4 2024	Q4 2025	Δ%	FY 2024	FY 2025	Δ%
Revenue	1,785	2,038	+14.2%	6,838	7,758	+13.5%
EBITDA	97	195	+101.4%	645	973	+50.9%
Margin	5.4%	9.6%	+4.2pp.	9.4%	12.5%	+3.1pp.
Profit before tax	80	179	+122.2%	579	912	+57.4%
Margin	4.5%	8.8%	+4.3pp.	8.5%	11.8%	+3.3pp.
Net Profit	75	161	+113.1%	526	802	+52.6%
Margin	4.2%	7.9%	+3.7pp.	7.7%	10.3%	+2.6pp.

Commentary

- **Insurance segment growth delivered strong growth in FY 2025**, driven by solid renewal activity and continued new-customer acquisition, underscoring sustained market momentum
- **Membership expanded by 6% YoY**, reflecting strong customer trust and a compelling value proposition
- **Gross written premium (GWP) increased by 9%** over the period, supported by high renewal rates and new business acquisition
- **Net profit rose 53% YoY**, despite the implementation of Pillar Two taxation, supported by resilient customer retention and solid investment income

Note: Cover vertical includes Insurance | * Increase in Corporate Tax rate from 9% in 2024 to 15% in 2025

Strong Growth in Free Cash Flow


AED Mn	FY 2024	FY 2025
EBITDA	4,119	4,781
Change in Net Working Capital ¹	122	(605)
Other operating activities	(21)	754
Maintenance CAPEX	(565)	(571)
Growth CAPEX	(386)	(526)
Adj. Free Cash Flow ²	3,269	3,833
Adj. Free Cash Flow to EBITDA	79%	80%

Commentary


- **Adjusted Free Cash Flow increased materially in FY25 compared with the prior year**, primarily driven by higher EBITDA generation across the Group
- **Other operating activities improved YoY**, mainly driven by restricted cash movement and reinsurance contract liabilities

Working Capital Changes (in AED Mn)

FY 2025



Total Capex / % of Revenues (in AED Mn, %)



¹ Working capital does not include insurance contract liabilities, reinsurance contract assets, other liabilities and restricted cash

² Adj. FCF is the sum of cash flow from operations and the capex additions incurred for PPE and intangibles



Strong Financial Position Supporting Strategic, Value-Driven Investments

Total Assets (AED Bn)

57.2

▲ +18% year-on-year

Cash & Bank Balance (AED Bn)

7.7

▼ -36% year-on-year

Net Debt / EBITDA

2.5x

Post IFRS 16

Total Liabilities (AED Bn)

38.8

▲ +35% year-on-year

Total Lease Liabilities (AED Bn)

15.0

▲ +20% year-on-year

Total Non-Lease Liabilities (AED Bn)

23.8

▲ +46% year-on-year

Total Bank Debt (AED Bn)

3.2

▲ +75% year-on-year

Net Debt (AED Bn)

11.8

▲ +228% year-on-year

Commentary

- **The balance sheet remains strong**, with a Net Debt to EBITDA ratio of **2.5x**
- The Group proactively strengthened its capital structure through the **early repayment** of AED 1.85 billion in outstanding debt originally due in 2027
- PureHealth **completed the acquisition of Hellenic Healthcare Group in October 2025** for EUR 800 million (AED 3.49 billion). The transaction was funded through internal cash resources and reflects management's strategic capital allocation to expand the Group's regional footprint and support long-term value creation
- Bank Debt stands at AED 3.2 billion, which relates entirely to the absorption of Hellenic Health Group's debt



Balanced Approach to Capital Allocation Driving Long-Term Value Creation



Shareholder Returns Disciplined Capital Return Policy¹

Target annual cash payout of

30% of Distributable Net Profit

- Residual dividend policy targeting annual cash payout of 30% of distributable net profit
- Balancing sustainable shareholder returns with long-term growth and capital requirements
- In years where PureHealth undertakes material M&A or other significant strategic investments and CapEx, the Company will aim for a c.30% target payout
- The Board may recommend a lower payout, when appropriate, to preserve financial flexibility, maintain a prudent capital structure, and support value-accretive growth opportunities



Inorganic Growth Clear Strategy to Drive Value Accretive M&A

- Pursuing disciplined M&A and Bolt-on to enhance the platform
- Selective international expansion in priority growth markets
- Clear financial benchmarks, prioritizing sustainable value creation



Organic Growth Investing in Our Core Strengths

- Targeted investments in high-margin, complex medical capabilities and building Centres of Excellence
- Enhancing operational efficiency through technology, AI and process improvements
- Building digital platforms and customer focused solutions

1. Dividend payout is subject to financial performance, cash flow generation, distributable reserves, leverage considerations, investments in long-term growth (incl M&A), and applicable legal and regulatory requirements. Subject to Board recommendation and shareholder approval.



Outlook & Guidance



Medium-Term Strategic and Financial Targets

	Revenue Growth	International Revenue Share ¹	Care: EBITDA Margin	CAPEX as % of Revenue	Net Debt ² / EBITDA	Dividend Payout Ratio
FY 2025	+5.7%	26.4%	19.5%	4.0%	2.5x	30%
Medium-Term Targets (2026-2029)	Mid-to-High Teens (including M&A)	c. 50%	Low 20s	<5%	3.0x	30%

Medium-term performance expectations, following FY 2025 results

Medium-term target applicable specifically to Healthcare and in view of continued Group-wide M&A activity

¹ Share of international business as % of revenue, after intercompany eliminations
² Net Debt includes lease liabilities, adjusted for restricted cash items



Appendix



Overview of Our Integrated Portfolio of Healthcare Assets

Care (Healthcare)

Hospitals



Diagnostics



Procurement



Technology



Cover (Insurance)

Health Insurance



FY 2025 Segment Value & Contribution in %

Revenue	AED 20,524 Mn (58%)	AED 1,139 Mn (3%)	AED 5,360 Mn (15%)	AED 654 Mn (2%)	AED 7,758 Mn (22%)
EBITDA	AED 3,174 Mn (64%)	AED 451 Mn (9%)	AED 277 Mn (6%)	AED 124 Mn (2%)	AED 973 Mn (19%)
Net Profit	AED 964 Mn (40%)	AED 349 Mn (14%)	AED 236 Mn (10%)	AED 73 Mn (3%)	AED 802 Mn (33%)
Total assets	AED 56.5 Bn (76%)	AED 3.2 Bn (4%)	AED 4.7 Bn (6%)	AED 1.0 Bn (1%)	AED 9.3 Bn (13%)

¹ As per segment note of financials



Built to Scale: A Platform for Global Growth and Strategic Value Creation

Enabling Expansion through Clinical Excellence, Cost Synergies, and Digital Infrastructure

Access to Global Growth

- Capturing growing private healthcare demand in developed markets
- Geographic risk diversification
- Currency risk diversification




Operational Synergies

- Global purchasing agreements with vendors driving cost savings
- Shared digital infrastructure across the group
- AI & Data Collaboration
- Cross-border clinical talent development and mobility to address critical healthcare workforce shortages



Clinical & Digital Uplift

- Transfer of advanced clinical protocols and technologies to enhance both the quality and breadth of services offered
- Expanding access to a broad network of sub-specialties to enhance patient experience



Strategic Positioning

- Positioning PureHealth as a world-class, future-ready healthcare group
- Establishing a scalable platform for expansion across developed markets and beyond





Continued International Expansion via Strategic Entry into Greece and Cyprus

Successful Completion of the HHG Acquisition, Consolidated from Q4 2025

35%


Market Share

In Greece –
private health services

24%


Market Share

In Cyprus –
private health services




€607m

2024 Net Revenue




11

Hospitals




23

Diagnostic Centers




1,600+

Licensed Beds



6,000+

IVF Cycles



6,500

Physicians

Largest Private Healthcare Operator in Greece & Cyprus

About HHG
Founded in 2018, HHG provides **world-class, comprehensive healthcare to over 1.4 million patients annually** in Greece & Cyprus

Specialties
Operations span **hospital care, diagnostics, genomics, assisted reproduction, home healthcare, medical supplies**, plus **training and development** through Heal Academy

Shareholding Structure



Shareholder	Percentage
PureHealth	60%
CVC Capital Partners	35%
Management	5%









Breakthrough Complex Care with Strong Clinical Performance







Transplants

33 Liver and 130 Kidney Transplants carried out in 2025 with a total of 794 Kidney Transplants since inception



Breakthrough Paediatric Cardiac Surgery

Performed a groundbreaking minimally invasive tricuspid valve replacement in a 14-year-old at SKMC, highlighting the facility’s advanced paediatric cardiac expertise



Dual-Organ Transplant in a Child

Completed a rare dual liver-kidney transplant for a 10-year-old with a congenital condition, followed by a sibling kidney transplant, showcasing complex paediatric transplant expertise



First-in-UAE Procedures

- Rhabdomyosarcoma tumor embolization (buccal cavity) in a 14-month-old child.
- Middle meningeal artery embolization for chronic subdural hematomas at SSMC



Microvascular Free-Tissue Transfer

Reconstruction of complex head and neck defects using advanced microvascular techniques



29 kg Ovarian Tumour Removal

Successful removal of a 29 kg ovarian tumor – Transforming patient outcomes



Complex Paediatric Care

SSMC team performed a rare procedure performing laparoscopic subtotal pancreatectomy in a 4-month baby for Nesidioblastosis



Groundbreaking Implants & Therapies

- SSMC team carried out 1st Auditory Brainstem Implant and Hypoglossal Nerve Implant for Sleep Apnea within the Abu Dhabi region, marking a major milestone in regional healthcare


Circle Health Group



Cytoreductive surgeries

- 100 Cytoreductive surgeries for Pseudomyxoma performed to date



Complex Cases - YTD

- 100 Revision Joints
- 40 Insertion of ICD
- 19 TAVI [Transcatheter Aortic Valve Implantation]
- 07 Repair of Tricuspid Valve



Robotic Assisted Procedures

- 3,158 robotic assisted procedures performed to date
- 700+ VELYS robotic surgeries performed to date



Spine Related

- 401 Complex spinal surgeries

Balance Sheet

AED Mn	FY 2024	FY 2025	Δ%
Total Non-Current Assets	25,844	37,141	44%
Right of use assets	11,019	12,671	15%
Intangible Assets	8,644	12,568	45%
Property & equipment	3,277	7,397	126%
Other non-current assets	2,904	4,504	55%
Total Current Assets	22,731	20,021	-12%
Trade & other receivables	4,843	5,923	22%
Cash & Bank Balance	11,978	7,706	-36%
Reinsurance contract assets	1,527	1,586	4%
Other current Assets	4,383	4,806	10%
Total Assets	48,575	57,162	18%
Total Non-Current Liabilities	16,757	24,032	43%
Lease liabilities	12,205	14,475	19%
Borrowings	1,834	2,834	54%
Employee end of service benefits	1,506	1,621	8%
Other non-current liabilities	1,212	5,103	321%
Total Current Liabilities	12,081	14,808	23%
Trade & other payables	7,576	9,294	23%
Lease liabilities	307	501	63%
Contract liability	57	61	7%
Borrowings	26	415	1484%
Other current liabilities	4,115	4,537	10%
Total Liabilities	28,838	38,840	35%
Total Equity	19,737	18,322	-7%

Income Statement

AED Mn	Q4 2024	Q4 2025	Δ%	FY 2024	FY 2025	Δ%
Revenue	6,892	7,211	+4.6%	25,848	27,312	+5.7%
Cost of sales	(5,654)	(5,600)	-1.1%	(19,202)	(20,579)	+7.2%
Gross profit	1,238	1,611	+30.1%	6,646	6,733	+1.3%
G&A expenses incl. selling & distribution	(1,150)	(1,240)	+7.8%	(4,735)	(4,732)	-0.1%
Finance costs	(243)	(287)	+18.3%	(848)	(865)	+2.0%
Other operating income	404	414	+2.4%	715	1,106	54.8%
Profit before tax	250	498	+99.4%	1,778	2,242	+26.1%
Income tax expense	30	(28)	-196.1%	(62)	(222)	+257.9%
Profit for the year	279	470	68.1%	1,716	2,020	+17.7%

Cash Flow Statement

AED Mn	Q4 2024	Q4 2025	Δ%	FY 2024	FY 2025	Δ%
Net Profit for the period before tax	250	498	+99%	1,778	2,242	+26%
Non-cash Adjustments	747	945	+26%	2,511	2,629	+5%
Working Capital Changes ¹	2,643	1,798	-32%	122	-605	-597%
Employees' end of service benefits paid net	-44	-43	-2%	-157	-191	+22%
Other	-813	36	-104%	-35	854	-2562%
Net cash, operating activities	2,783	3,235	+16%	4,219	4,929	+17%
Net cash, investing activities	374	-4,404	-1277%	-3,645	-6,250	+71%
Net cash, financing activities	-265	-304	+15%	237	-3,106	-1412%
Net changes in cash & cash equivalents during the period	2,893	-1,473	-151%	810	-4,427	-646%
FX rate changes during the period	-43	-3	-94%	-8	62	-844%
Cash & cash equivalents at the beginning of the period	5,939	5,900	-1%	7,987	8,789	+10%
Cash & cash equivalents at the end of the period	8,789	4,424	-50%	8,789	4,424	-50%

1) Working capital does not include reinsurance contract assets/liabilities, other liabilities and restricted cash

PURSHALTH⁺

PURSHALTH⁺

Investor Relations

purehealth.ae/investor-relations

ir@purehealth.ae